Treatment of Bolivian hemorrhagic fever with intravenous ribavirin

Paul E. Kilgore, Thomas Ksiazek, Pierre E. Rollin, James N. Mills, Mario R. Villagra, Mario J. Montenegro, Maria A. Costales, Luis C. Paredes, C. J. Peters

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

Bolivian hemorrhagic fever (BHF) is a potentially severe febrile illness caused by Machupo virus (family Arenaviridae). Initial symptoms include headache, fever, arthralgia, and myalgia. In the later stages of this illness, patients may develop hemorrhagic manifestations including subconjunctival hemorrhage, epistaxis, hematemesis, melena, and hematuria, as well as neurological signs including tremor, seizures, and coma. During the BHF epidemics of the 1960s, convalescent-phase immune plasma from survivors of BHF was administered to selected patients infected with Machupo virus. However, there is currently a paucity of survivors of BHP who can donate immune plasma, and there is no active program for collection and storage of BHF immune plasma; therefore, we had the opportunity to offer intravenous ribavirin to two of three patients with this potentially life-threatening infection. One patient with laboratory-confirmed Machupo virus infection who received ribavirin recovered without sequelae, as did a second patient with suspected BHF whose epidemiological and clinical features were similar to those of the first patient. This report describes the first use of intravenous ribavirin therapy for BHF in humans, and the results suggest the need for more extensive clinical studies to assess the usefulness of ribavirin for treating BHF.

Original languageEnglish (US)
Pages (from-to)718-722
Number of pages5
JournalClinical Infectious Diseases
Volume24
Issue number4
StatePublished - 1997
Externally publishedYes

Fingerprint

American Hemorrhagic Fever
Ribavirin
New World Arenaviruses
Therapeutics
Survivors
Arenaviridae
Fever
Melena
Hematemesis
Epistaxis
Myalgia
Arthralgia
Tremor
Hematuria
Virus Diseases
Coma
Headache
Seizures
Hemorrhage

ASJC Scopus subject areas

  • Immunology

Cite this

Kilgore, P. E., Ksiazek, T., Rollin, P. E., Mills, J. N., Villagra, M. R., Montenegro, M. J., ... Peters, C. J. (1997). Treatment of Bolivian hemorrhagic fever with intravenous ribavirin. Clinical Infectious Diseases, 24(4), 718-722.

Treatment of Bolivian hemorrhagic fever with intravenous ribavirin. / Kilgore, Paul E.; Ksiazek, Thomas; Rollin, Pierre E.; Mills, James N.; Villagra, Mario R.; Montenegro, Mario J.; Costales, Maria A.; Paredes, Luis C.; Peters, C. J.

In: Clinical Infectious Diseases, Vol. 24, No. 4, 1997, p. 718-722.

Research output: Contribution to journalArticle

Kilgore, PE, Ksiazek, T, Rollin, PE, Mills, JN, Villagra, MR, Montenegro, MJ, Costales, MA, Paredes, LC & Peters, CJ 1997, 'Treatment of Bolivian hemorrhagic fever with intravenous ribavirin', Clinical Infectious Diseases, vol. 24, no. 4, pp. 718-722.
Kilgore PE, Ksiazek T, Rollin PE, Mills JN, Villagra MR, Montenegro MJ et al. Treatment of Bolivian hemorrhagic fever with intravenous ribavirin. Clinical Infectious Diseases. 1997;24(4):718-722.
Kilgore, Paul E. ; Ksiazek, Thomas ; Rollin, Pierre E. ; Mills, James N. ; Villagra, Mario R. ; Montenegro, Mario J. ; Costales, Maria A. ; Paredes, Luis C. ; Peters, C. J. / Treatment of Bolivian hemorrhagic fever with intravenous ribavirin. In: Clinical Infectious Diseases. 1997 ; Vol. 24, No. 4. pp. 718-722.
@article{c79c204363d448e0a9175efb24e2342f,
title = "Treatment of Bolivian hemorrhagic fever with intravenous ribavirin",
abstract = "Bolivian hemorrhagic fever (BHF) is a potentially severe febrile illness caused by Machupo virus (family Arenaviridae). Initial symptoms include headache, fever, arthralgia, and myalgia. In the later stages of this illness, patients may develop hemorrhagic manifestations including subconjunctival hemorrhage, epistaxis, hematemesis, melena, and hematuria, as well as neurological signs including tremor, seizures, and coma. During the BHF epidemics of the 1960s, convalescent-phase immune plasma from survivors of BHF was administered to selected patients infected with Machupo virus. However, there is currently a paucity of survivors of BHP who can donate immune plasma, and there is no active program for collection and storage of BHF immune plasma; therefore, we had the opportunity to offer intravenous ribavirin to two of three patients with this potentially life-threatening infection. One patient with laboratory-confirmed Machupo virus infection who received ribavirin recovered without sequelae, as did a second patient with suspected BHF whose epidemiological and clinical features were similar to those of the first patient. This report describes the first use of intravenous ribavirin therapy for BHF in humans, and the results suggest the need for more extensive clinical studies to assess the usefulness of ribavirin for treating BHF.",
author = "Kilgore, {Paul E.} and Thomas Ksiazek and Rollin, {Pierre E.} and Mills, {James N.} and Villagra, {Mario R.} and Montenegro, {Mario J.} and Costales, {Maria A.} and Paredes, {Luis C.} and Peters, {C. J.}",
year = "1997",
language = "English (US)",
volume = "24",
pages = "718--722",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Treatment of Bolivian hemorrhagic fever with intravenous ribavirin

AU - Kilgore, Paul E.

AU - Ksiazek, Thomas

AU - Rollin, Pierre E.

AU - Mills, James N.

AU - Villagra, Mario R.

AU - Montenegro, Mario J.

AU - Costales, Maria A.

AU - Paredes, Luis C.

AU - Peters, C. J.

PY - 1997

Y1 - 1997

N2 - Bolivian hemorrhagic fever (BHF) is a potentially severe febrile illness caused by Machupo virus (family Arenaviridae). Initial symptoms include headache, fever, arthralgia, and myalgia. In the later stages of this illness, patients may develop hemorrhagic manifestations including subconjunctival hemorrhage, epistaxis, hematemesis, melena, and hematuria, as well as neurological signs including tremor, seizures, and coma. During the BHF epidemics of the 1960s, convalescent-phase immune plasma from survivors of BHF was administered to selected patients infected with Machupo virus. However, there is currently a paucity of survivors of BHP who can donate immune plasma, and there is no active program for collection and storage of BHF immune plasma; therefore, we had the opportunity to offer intravenous ribavirin to two of three patients with this potentially life-threatening infection. One patient with laboratory-confirmed Machupo virus infection who received ribavirin recovered without sequelae, as did a second patient with suspected BHF whose epidemiological and clinical features were similar to those of the first patient. This report describes the first use of intravenous ribavirin therapy for BHF in humans, and the results suggest the need for more extensive clinical studies to assess the usefulness of ribavirin for treating BHF.

AB - Bolivian hemorrhagic fever (BHF) is a potentially severe febrile illness caused by Machupo virus (family Arenaviridae). Initial symptoms include headache, fever, arthralgia, and myalgia. In the later stages of this illness, patients may develop hemorrhagic manifestations including subconjunctival hemorrhage, epistaxis, hematemesis, melena, and hematuria, as well as neurological signs including tremor, seizures, and coma. During the BHF epidemics of the 1960s, convalescent-phase immune plasma from survivors of BHF was administered to selected patients infected with Machupo virus. However, there is currently a paucity of survivors of BHP who can donate immune plasma, and there is no active program for collection and storage of BHF immune plasma; therefore, we had the opportunity to offer intravenous ribavirin to two of three patients with this potentially life-threatening infection. One patient with laboratory-confirmed Machupo virus infection who received ribavirin recovered without sequelae, as did a second patient with suspected BHF whose epidemiological and clinical features were similar to those of the first patient. This report describes the first use of intravenous ribavirin therapy for BHF in humans, and the results suggest the need for more extensive clinical studies to assess the usefulness of ribavirin for treating BHF.

UR - http://www.scopus.com/inward/record.url?scp=0030935067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030935067&partnerID=8YFLogxK

M3 - Article

VL - 24

SP - 718

EP - 722

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 4

ER -